0001209191-22-050645.txt : 20220919
0001209191-22-050645.hdr.sgml : 20220919
20220919192431
ACCESSION NUMBER: 0001209191-22-050645
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20220909
FILED AS OF DATE: 20220919
DATE AS OF CHANGE: 20220919
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dubois-Stringfellow Nathalie
CENTRAL INDEX KEY: 0001947007
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 221251785
MAIL ADDRESS:
STREET 1: C/O SANGAMO THERAPEUTICS, INC.
STREET 2: 7000 MARINA BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2022-09-09
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001947007
Dubois-Stringfellow Nathalie
C/O SANGAMO THERAPEUTICS, INC.
7000 MARINA BOULEVARD
BRISBANE
CA
94005
0
1
0
0
SVP-Chief Development Officer
Common Stock
94954
D
Stock Option (Right to Buy)
3.50
2027-01-26
Common Stock
54229
D
Stock Option (Right to Buy)
20.05
2028-01-24
Common Stock
30000
D
Stock Option (Right to Buy)
9.03
2029-02-25
Common Stock
15628
D
Stock Option (Right to Buy)
6.80
2030-02-25
Common Stock
55000
D
Stock Option (Right to Buy)
11.19
2031-02-25
Common Stock
48000
D
Stock Option (Right to Buy)
5.90
2032-02-25
Common Stock
121770
D
Includes: (a) 9,168 shares of common stock subject to the Reporting Person's February 25, 2020 restricted stock unit ("RSU") grant that will vest in one final annual installment on February 25, 2023 and (b) 16,000 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 8,000 shares on each of February 25, 2023 and 2024. Each such RSU grant vests with respect to 1/3rd of the shares subject to such RSU grant in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP.
Includes 45,100 shares of common stock subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Fully vested and exercisable.
One-quarter (1/4) of the shares subject to the option vested and became exercisable on the anniversary of the February 25, 2019 grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
One-quarter (1/4) of the shares subject to the option vested and became exercisable on the anniversary of the February 25, 2020 grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
One-quarter (1/4) of the shares subject to the option vested and became exercisable on the anniversary of the February 25, 2021 grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Nathalie Dubois-Stringfellow, by /s/ Ron A. Metzger, Attorney-in-Fact
2022-09-19
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints
Prathyusha Duraibabu, Scott Willoughby, Nikunj Jain, Stephen de Guzman and Ron
A. Metzger of Cooley LLP, counsel to Sangamo Therapeutics, Inc. (the "Company"),
with full power of substitution, the undersigned's true and lawful
attorney-in-fact to:
1. execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer or director, as the case may be, of the Company, Forms 3,
4 and 5 (and any amendments thereto) in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules
thereunder;
2. do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4 or 5,
complete and execute any amendments thereto, and timely file such form with the
U.S. Securities and Exchange Commission (the "SEC") and any securities exchange
or similar authority, including without limitation the filing of a Form ID or
any other documents necessary or appropriate to enable the undersigned to file
the Forms 3, 4 and 5 electronically with the SEC;
3. seek or obtain, as the undersigned's representative and on the
undersigned's behalf, information on transactions in the Company's securities
from any broker or financial institution, and the undersigned hereby authorizes
any such person to release any such information to each of the undersigned's
attorneys-in-fact appointed by this Power of Attorney and approves and ratifies
any such release of information; and
4. take any other action in connection with the foregoing which, in the
opinion of such attorney-in-fact, may be of benefit to, in the best interest of,
or legally required by or for, the undersigned, it being understood that the
documents executed by such attorney-in-fact on behalf of the undersigned
pursuant to this Power of Attorney shall be in such form and shall contain such
information and disclosure as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever required,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this Power of Attorney and the rights and powers herein
granted.
The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request and on the behalf of the undersigned, are not
assuming, nor is the Company assuming, any of the undersigned's responsibilities
to comply with, or any liability for the failure to comply with, any provision
of Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 or 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to each
of the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of
this 14th day of September, 2022.
/s/ Nathalie Dubois-Stringfellow